Congestive heart failure (CHF) is a physiological condition that has an adverse impact on the pumping efficiency of the cardiac muscles. It characterizes the accumulation of fluid around the heart leading to inefficient pumping. The onset of CHF is marked by the failure of the ventricles to pump sufficient volume of blood to the body organs. This eventually leads to deposition of fluid in the lungs, abdomen, liver, and lower body. CHF is treated by a number of devices that maintain heart rhythm, such as pacemakers, cardiac resynchronization therapy (CRT), implantable cardioverter defibrillators (ICDs), and ventricular assist devices (VADs).
1.1 Company Overview
1.2 Company Snapshot
1.3 Operating Business Segment
1.4 Business Performance
1.5 Key Strategic moves and Development
TABLE 1. BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
TABLE 2. BOSTON SCIENTIFIC CORPORATION: OPERATING SEGMENTS
FIG. 1. BOSTON SCIENTIFIC CORPORATION: NET SALES, 20132015, ($MILLION)
FIG. 2. BOSTON SCIENTIFIC CORPORATION: REVENUE BY BUSINESS SEGMENT, 2015 (%)
FIG. 3. BOSTON SCIENTIFIC CORPORATION: RHYTHM MANAGEMENT REVENUE BY SUB-SEGMENT, 2015 (%)
FIG. 4. BOSTON SCIENTIFIC CORPORATION: REVENUE BY GEOGRAPHY, 2015 (%)
FIG. 5. BOSTON SCIENTIFIC CORPORATION: SWOT ANALYSIS
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of the scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save the time of readers